TENX Description — Tenax Therapeutics Inc
Tenax Therapeutics is focused on identifying, developing and commercializing late-stage pharmaceutical therapeutic products for cardiovascular and pulmonary diseases. Co. owns a license granting Life Newco, Inc., its wholly owned subsidiary, a sublicensable right to develop and commercialize pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion / 5ml vial in the U.S. and Canada. Co.'s programs include: Levosimendan, which is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib (marketed in the U.S. as Gleevec®), which is a tyrosine kinase inhibitor.